-

Daiichi Sankyo Confirms that a Texas Court has Entered Judgment on the Jury Verdict in Seagen Patent Dispute

  • No Enhancement of Damages Awarded by Court Despite Jury’s Finding of Willfulness

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo Co., Ltd. (TSE: 4568) (hereinafter, Daiichi Sankyo) confirmed today that the U.S. District Court for the Eastern District of Texas has entered judgment on the April 8, 2022 jury verdict finding that ENHERTU® infringes Seagen’s U.S. Patent 10,808,039 (the ’039 patent), that the infringement was willful, and awarding Seagen $41.8 million in damages. Despite the jury’s finding of willfulness, the Court decided under the totality of the circumstances that enhancement (an increase) of damages was not warranted, and therefore did not enhance the damages award.

Daiichi Sankyo will continue to vigorously defend its rights and explore available post-trial motions and remedies to contest the judgment and damages awarded to Seagen.

The Court has not yet addressed whether to award a running royalty on future sales of ENHERTU® until the expiry of the ’039 patent in 2024. Any impact on Daiichi Sankyo’s consolidated financials for fiscal year ending March 31, 2023, is currently being evaluated and will be announced as soon as possible.

About Daiichi Sankyo

Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology for our purpose “to contribute to the enrichment of quality of life around the world.” In addition to our current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as well as other diseases with high unmet medical needs. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation to realize our 2030 Vision to become an “Innovative Global Healthcare Company Contributing to the Sustainable Development of Society.” For more information, please visit: www.daiichisankyo.com.

Contacts

U.S.
Kim Wix
Daiichi Sankyo, Inc.
kwix@dsi.com
+1 973-992-6633 (office)

Japan:
Masashi Kawase
Daiichi Sankyo Co., Ltd.
kawase.masashi.a2@daiichisankyo.co.jp
++81 3 6225 1126 (office)

Investor Relations Contact:
DaiichiSankyoIR@daiichisankyo.co.jp

Daiichi Sankyo Co., Ltd.

TOKYO:4568

Release Versions

Contacts

U.S.
Kim Wix
Daiichi Sankyo, Inc.
kwix@dsi.com
+1 973-992-6633 (office)

Japan:
Masashi Kawase
Daiichi Sankyo Co., Ltd.
kawase.masashi.a2@daiichisankyo.co.jp
++81 3 6225 1126 (office)

Investor Relations Contact:
DaiichiSankyoIR@daiichisankyo.co.jp

More News From Daiichi Sankyo Co., Ltd.

Federal Circuit Court of Appeals Vacates Infringement Judgment and Damages Award in Dispute between Daiichi Sankyo and Seagen

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--On December 2, the U.S. Court of Appeals for the Federal Circuit (the Federal Circuit) reversed a decision from the U.S. District Court for the Eastern District of Texas that found Seagen Inc’s U.S. Patent No. 10,808,039 (the ’039 patent) not invalid (the Texas decision). In view of the reversal, the Federal Circuit vacated the Texas court’s related infringement judgment and damages award against Daiichi Sankyo. In a separate decision, the Federal C...

DATROWAY® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Overall Survival as First-Line Therapy for Patients with Metastatic Triple Negative Breast Cancer for Whom Immunotherapy Was Not an Option in TROPION-Breast02

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Positive topline results from the TROPION-Breast02 phase 3 trial showed DATROWAY® (datopotamab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) compared to investigator’s choice of chemotherapy as first-line treatment for patients with locally recurrent inoperable or metastatic triple negative breast cancer (TNBC) for...

Daiichi Sankyo Establishes Third Research Institute in San Diego

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) has established Daiichi Sankyo Research Institute in San Diego, representing the third research institute established outside of the company’s flagship research center in Japan since the opening of locations in Boston and Munich in 2024. “Establishing a dedicated scientific presence in San Diego marks a significant milestone for Daiichi Sankyo as we continue to deepen our long-standing relationships in one of the world’s l...
Back to Newsroom